Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.58 |
| ▸ | MIF | P14174 | 1/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29535211 | 1.00 | TDO2 (0.58) | TDO2MIFNFE2L2HTTKDM4E | |
| SCHEMBL65191 | 1.00 | TDO2 (0.58) | TDO2MIFNFE2L2HTTKDM4E | |
| SCHEMBL14086377 | 1.00 | TDO2 (0.58) | TDO2MIFNFE2L2HTTKDM4E | |
| Guanidine SCHEMBL7156565 | 0.90 | TDO2 (0.50) | TDO2MIFNFE2L2HTTKDM4E | |
| Guanidine SCHEMBL7156567 | 0.90 | TDO2 (0.50) | TDO2MIFNFE2L2HTTKDM4E | |
| SCHEMBL29407005 | 0.86 | MIF (0.71) | TDO2MIFNFE2L2HTTKDM4E | |
| SCHEMBL716629 | 0.86 | MIF (0.71) | TDO2MIFNFE2L2HTTKDM4E | |
| SCHEMBL1920415 | 0.86 | MIF (0.71) | TDO2MIFNFE2L2HTTKDM4E | |
| SCHEMBL716630 | 0.86 | MIF (0.71) | TDO2MIFNFE2L2HTTKDM4E | |
| SCHEMBL1674366 | 0.85 | MIF (0.54) | TDO2MIFKDM4EALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| CN-118930859-A | Cinnamic acid modified polyarylene sulfide and preparation method thereof | 新凝合科技(成都)有限公司 | 2024-11-12 | — | — | CN | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | claimed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | claimed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| EP-1747059-A1 | PERVAPORATION COMPOSITE MEMBRANES | McMaster University (CA) | 2007-01-31 | — | — | EP | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060000778-A1 | high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers | MCMASTER UNIVERSITY (CA) | 2006-01-05 | — | — | US | claimed |
| WO-2005102503-A1 | PERVAPORATION COMPOSITE MEMBRANES | MCMASTER UNIVERSITY (CA) | 2005-11-03 | — | — | WO | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | KUMQUAT BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | disclosed |
| CN-118930859-A | Cinnamic acid modified polyarylene sulfide and preparation method thereof | 新凝合科技(成都)有限公司 | 2024-11-12 | — | — | CN | disclosed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20230044323-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | KUMQUAT BIOSCIENCES INC. | 2023-02-09 | — | — | US | disclosed |
| CN-115286625-A | Glutaminase allosteric site covalent inhibitor and preparation method and application thereof | 浙江工业大学 | 2022-11-04 | — | — | CN | disclosed |
| EP-4073242-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | Kumquat Biosciences Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| CN-115103907-A | Compositions and methods for enhancing immune activity | 金橘生物科技公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-110114353-B | Benzo [ b ] thiophene amide derivative and application thereof | 山东大学 | 2022-04-22 | — | — | CN | disclosed |
| WO-2021119554-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | KUMQUAT BIOSCIENCES INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | disclosed |
| EP-2226192-B1 | DRYING SUBSTANCES, PREPARATION AND USE THEREOF | ORIDION MEDICAL 1987 LTD (IL) | 2016-08-31 | — | — | EP | disclosed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | disclosed |
| US-9340574-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-05-17 | — | — | US | disclosed |
| EP-2226116-B1 | Drying tube, preparation and use thereof | ORIDION MEDICAL 1987 LTD (IL) | 2016-04-20 | — | — | EP | disclosed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150283519-A1 | DRYING SUBSTANCES, PREPARATION AND USE THEREOF | ORIDION MEDICAL 1987 LTD. (IL) | 2015-10-08 | — | — | US | disclosed |
| US-9150510-B2 | Amino acid derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20150239931-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2015-08-27 | — | — | US | disclosed |
| US-9090766-B2 | Drying substances, preparation and use thereof | ORIDION MEDICAL 1987 LTD. (IL) | 2015-07-28 | — | — | US | disclosed |
| US-9067035-B2 | Drying substances, preparation and use thereof | ORIDION MEDICAL (1987) LTD. (IL) | 2015-06-30 | — | — | US | disclosed |
| US-8852937-B2 | Small organic molecule regulators of cell proliferation | CURIS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8852937-B2 | Small organic molecule regulators of cell proliferation | CURIS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8852937-B2 | Small organic molecule regulators of cell proliferation | CURIS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20140230652-A1 | DRYING SUBSTANCES, PREPARATION AND USE THEREOF | ORIDION MEDICAL (1987) LTD. (IL) | 2014-08-21 | — | — | US | disclosed |
| US-8764888-B2 | Drying substances, preparation and use thereof | ORIDION MEDICAL 1987 LTD. (IL) | 2014-07-01 | — | — | US | disclosed |
| US-8747752-B2 | Drying substances, preparation and use thereof | ORIDION MEDICAL (1987) LTD. (IL) | 2014-06-10 | — | — | US | disclosed |
| WO-2014055768-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2014-04-10 | — | — | WO | disclosed |
| US-20130338523-A1 | DRYING SUBSTANCES, PREPARATION AND USE THEREOF | ORIDION MEDICAL (1987) LTD. (IL) | 2013-12-19 | — | — | US | disclosed |
| EP-2666795-A1 | Drying substances, preparation and use thereof | Oridion Medical 1987 Ltd. (IL) | 2013-11-27 | — | — | EP | disclosed |
| US-8540806-B2 | Drying substances, preparation and use thereof | ORIDION MEDICAL (1987) LTD. (IL) | 2013-09-24 | — | — | US | disclosed |
| US-20130116589-A1 | DRYING SUBSTANCES, PREPARATION AND USE THEREOF | ORIDION MEDICAL (1987) LTD. (IL) | 2013-05-09 | — | — | US | disclosed |
| US-8366811-B2 | Drying substances, preparation and use thereof | ORIDION MEDICAL (1987) LTD. (IL) | 2013-02-05 | — | — | US | disclosed |
| US-20120245184-A1 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | ADERANS RESEARCH INSTITUTE, INC. | 2012-09-27 | — | — | US | disclosed |
| US-20120245184-A1 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | ADERANS RESEARCH INSTITUTE, INC. | 2012-09-27 | — | — | US | disclosed |
| US-20120245184-A1 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | ADERANS RESEARCH INSTITUTE, INC. | 2012-09-27 | — | — | US | disclosed |
| US-8273747-B2 | tert-Butyl (4-((4'-cyano-4-methoxy-biphenyl-3-ylmethyl)-amino)-cyclohexyl)-methyl-carbamate; hedgehog pathway agonists; alopecia; angiogenesis; wound healing; alzheimer's disease; inhibit aging effects on skin | CURIS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273747-B2 | tert-Butyl (4-((4'-cyano-4-methoxy-biphenyl-3-ylmethyl)-amino)-cyclohexyl)-methyl-carbamate; hedgehog pathway agonists; alopecia; angiogenesis; wound healing; alzheimer's disease; inhibit aging effects on skin | CURIS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273747-B2 | tert-Butyl (4-((4'-cyano-4-methoxy-biphenyl-3-ylmethyl)-amino)-cyclohexyl)-methyl-carbamate; hedgehog pathway agonists; alopecia; angiogenesis; wound healing; alzheimer's disease; inhibit aging effects on skin | CURIS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2491026-A1 | NOVEL HETEROARYL IMIDAZOLES AND HETEROARYL TRIAZOLES AS GAMMA-SECRETASE MODULATORS | Pfizer Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20120202787-A1 | Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators | PFIZER INC. | 2012-08-09 | — | — | US | disclosed |
| WO-2012040321-A3 | METHODS AND APPARATUS FOR EHNANCED GAS DISTRIBUTION | GRUPO PETROTEMEX, S.A. DE C.V. (MX) | 2012-05-10 | — | — | WO | disclosed |
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| US-8129425-B2 | Contacting cell with hedgehog antagonist; moderator of cell proliferative, cell differentiation | CURIS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129425-B2 | Contacting cell with hedgehog antagonist; moderator of cell proliferative, cell differentiation | CURIS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129425-B2 | Contacting cell with hedgehog antagonist; moderator of cell proliferative, cell differentiation | CURIS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8124602-B2 | Compounds for the treatment of multi-drug resistant bacterial infections | ASTRAZENECA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| EP-2406256-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| EP-2406251-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| EP-1981881-B1 | TETRAHYDROPYRANE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-12-07 | — | — | EP | disclosed |
| WO-2011147951-A1 | CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS | PROSIDION LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
| EP-2345635-A1 | AMINO ACID DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20110172442-A1 | AMINO ACID DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| WO-2011048525-A1 | NOVEL HETEROARYL IMIDAZOLES AND HETEROARYL TRIAZOLES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| EP-2300477-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-7915295-B2 | Viricides; HIV antivirals effective against problematic drug escape mutants; N-[(1S,1aR,7bR)-4,7-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-1-yl]-N'-[5-(4-(sulfonamido)phenoxy)-2-pyridinyl]urea | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| US-20110071155-A1 | Tricyclic Nitrogen Containing Compounds And Their Use As Antibacterials | GLAXO GROUP LIMITED (GB) | 2011-03-24 | — | — | US | disclosed |
| EP-2289890-A1 | Compounds for the treatment of multi-drug resistant bacterial infections | AstraZeneca AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| US-7875715-B2 | 6-[({1-[2-(7-methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; antibacteria; methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative staphylococci (MRCNS), penicillin-resistant Streptococcus pneumoniae | ASTRAZENECA AB (SE) | 2011-01-25 | — | — | US | disclosed |
| EP-1956054-B1 | Phase change ink | XEROX CORP (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-1987040-B1 | ETHANOL OR 1,2-ETHANEDIOL CYCLOHEXYL ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-7820655-B2 | Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-10-26 | — | — | US | disclosed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010103335-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010103334-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| US-20100226824-A1 | Drying substances, preparation and use thereof | ORIDION MEDICAL (1987) LTD. (IL) | 2010-09-09 | — | — | US | disclosed |
| US-20100226823-A1 | Drying substances, preparation and use thereof | ORIDION MEDICAL (1987) LTD. (IL) | 2010-09-09 | — | — | US | disclosed |
| US-20100224066-A1 | Drying substances, preparation and use thereof | ORIDION MEDICAL (1987) LTD. (IL) | 2010-09-09 | — | — | US | disclosed |
| EP-2226192-A1 | Drying substances, preparation and use thereof | Oridion Medical 1987 Ltd. (IL) | 2010-09-08 | — | — | EP | disclosed |
| EP-2226116-A2 | Drying substances, preparation and use thereof | Oridion Medical 1987 Ltd. (IL) | 2010-09-08 | — | — | EP | disclosed |
| EP-2226341-A2 | Drying substances, preparation and use thereof | Oridion Medical 1987 Ltd. (IL) | 2010-09-08 | — | — | EP | disclosed |
| US-20100221398-A1 | PRESERVATIVE | DSM IP ASSETS B.V. (NL) | 2010-09-02 | — | — | US | disclosed |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | disclosed |
| US-20100137353-A1 | TRICYCLIC COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| EP-2176262-A1 | TRICYCLIC COMPOUNDS AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2010-04-21 | — | — | EP | disclosed |
| EP-1701942-B1 | NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2009-12-09 | — | — | EP | disclosed |
| WO-2009141399-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
| US-7604746-B2 | high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers | MCMASTER UNIVERSITY (CA) | 2009-10-20 | — | — | US | disclosed |
| EP-1611104-B1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-7517992-B2 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-20090092975-A1 | SELECTABLE MARKER | MOLOGIC LTD (GB) | 2009-04-09 | — | — | US | disclosed |
| US-20090005368-A1 | such as 6-({trans-4-[(1R)-1-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-cyclohexylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one for treating infections from Streptococcus pneumoniae, Haemophilus influenzae, Moraxella, Staphylococcus, Enterococcus | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-01-01 | — | — | US | disclosed |
| EP-1996579-A2 | ANTIBIOTIC COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2008-12-03 | — | — | EP | disclosed |
| EP-1337517-B1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2008-11-26 | — | — | EP | disclosed |
| EP-1987040-A1 | ETHANOL OR 1,2-ETHANEDIOL CYCLOHEXYL ANTIBIOTIC DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008128962-A1 | TRICYCLIC COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| EP-1981881-A1 | TETRAHYDROPYRANE ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20080207740-A1 | tert-Butyl {4-[(4'-cyano-4-methoxy-biphenyl-3-ylmethyl)-amino]-cyclohexyl}-methyl-carbamate; hedgehog pathway agonists; to modulate proliferation or differentiation in a cell or tissue in vivo or vitro; alopecia; angiogenesis; wound healing; alzheimer's disease; to inhibit aging effects on skin | CURIS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207740-A1 | tert-Butyl {4-[(4'-cyano-4-methoxy-biphenyl-3-ylmethyl)-amino]-cyclohexyl}-methyl-carbamate; hedgehog pathway agonists; to modulate proliferation or differentiation in a cell or tissue in vivo or vitro; alopecia; angiogenesis; wound healing; alzheimer's disease; to inhibit aging effects on skin | CURIS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207740-A1 | tert-Butyl {4-[(4'-cyano-4-methoxy-biphenyl-3-ylmethyl)-amino]-cyclohexyl}-methyl-carbamate; hedgehog pathway agonists; to modulate proliferation or differentiation in a cell or tissue in vivo or vitro; alopecia; angiogenesis; wound healing; alzheimer's disease; to inhibit aging effects on skin | CURIS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1958993-A1 | Phase change inks containing colorant compounds | Xerox Corporation (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20080193423-A1 | Small organic molecule regulators of cell proliferation | CURIS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080193423-A1 | Small organic molecule regulators of cell proliferation | CURIS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080193423-A1 | Small organic molecule regulators of cell proliferation | CURIS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194637-A1 | Small organic molecule regulators of cell proliferation | CURIS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194637-A1 | Small organic molecule regulators of cell proliferation | CURIS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194637-A1 | Small organic molecule regulators of cell proliferation | CURIS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1956054-A2 | Colorant compounds | Xerox Corporation (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080187664-A1 | Phase change inks containing colorant compounds | XEROX CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-20080184910-A1 | Mixture of basic dye and wax | XEROX CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-20080182859-A1 | tert-Butyl {4-[(4'-cyano-4-methoxy-biphenyl-3-ylmethyl)-amino]-cyclohexyl}-methyl-carbamate; hedgehog pathway agonists; to modulate proliferation or differentiation in a cell or tissue in vivo or vitro; alopecia; angiogenesis; wound healing; alzheimer's disease; to inhibit aging effects on skin | CURIS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182859-A1 | tert-Butyl {4-[(4'-cyano-4-methoxy-biphenyl-3-ylmethyl)-amino]-cyclohexyl}-methyl-carbamate; hedgehog pathway agonists; to modulate proliferation or differentiation in a cell or tissue in vivo or vitro; alopecia; angiogenesis; wound healing; alzheimer's disease; to inhibit aging effects on skin | CURIS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182859-A1 | tert-Butyl {4-[(4'-cyano-4-methoxy-biphenyl-3-ylmethyl)-amino]-cyclohexyl}-methyl-carbamate; hedgehog pathway agonists; to modulate proliferation or differentiation in a cell or tissue in vivo or vitro; alopecia; angiogenesis; wound healing; alzheimer's disease; to inhibit aging effects on skin | CURIS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080153873-A1 | DIHYDROBENZOFURANYL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-26 | — | — | US | disclosed |
| WO-2008057468-A1 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | CURIS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057468-A1 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | CURIS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057469-A1 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | WYETH (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057469-A1 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | WYETH (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057497-A2 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | CURIS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057497-A2 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | CURIS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20080070951-A1 | Non-Nucleotide Reverse Transcriptase Inhibitors | MEDIVIR AB (SE) | 2008-03-20 | — | — | US | disclosed |
| US-20080058521-A1 | Processes for the preparation of compounds | WYETH (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058521-A1 | Processes for the preparation of compounds | WYETH (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058521-A1 | Processes for the preparation of compounds | WYETH (US) | 2008-03-06 | — | — | US | disclosed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2007105154-A2 | ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007093963-A1 | ETHANOL OR 1,2-ETHANEDIOL CYCLOHEXYL ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007089669-A2 | PROCESSES FOR THE PREPARATION OF COMPOUNDS WHICH MODULATE CELL PROLIFERATION | WYETH (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089669-A2 | PROCESSES FOR THE PREPARATION OF COMPOUNDS WHICH MODULATE CELL PROLIFERATION | WYETH (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007086016-A1 | TETRAHYDROPYRANE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-02 | — | — | WO | disclosed |
| EP-1799676-A2 | NEW BICYCLIC ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2007-06-27 | — | — | EP | disclosed |
| US-20060287385-A1 | Small organic molecule regulators of cell proliferation | CURIS, INC. | 2006-12-21 | — | — | US | disclosed |
| US-7144881-B2 | Arylcyclopropylcarboxylic amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| US-7115653-B2 | Small organic molecule regulators of cell proliferation | CURIS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1701942-A1 | NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2006-09-20 | — | — | EP | disclosed |
| US-20060178515-A1 | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-08-10 | — | — | US | disclosed |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2006-07-27 | — | — | US | disclosed |
| EP-1565190-A4 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL MYERS SQUIBB CO (US) | 2006-04-26 | — | — | EP | disclosed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| WO-2006032466-A2 | NEW BICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-30 | — | — | WO | disclosed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | disclosed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | disclosed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | disclosed |
| US-20060000778-A1 | high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers | MCMASTER UNIVERSITY (CA) | 2006-01-05 | — | — | US | disclosed |
| EP-1611104-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-01-04 | — | — | EP | disclosed |
| EP-1436287-A4 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | CURIS INC (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | disclosed |
| EP-1565190-A2 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | Bristol-Myers Squibb Company (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2005066131-A1 | NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| US-20050153357-A1 | Bioactive sensors | EICHLER JUTTA (DE) | 2005-07-14 | — | — | US | disclosed |
| EP-1534276-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| EP-0755923-B1 | Ameliorant or remedy for symptoms caused by Ischemic diseases and Phenylpiperidine compounds useful therefor | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2005-05-04 | — | — | EP | disclosed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | disclosed |
| US-20050070578-A1 | Small organic molecule regulators of cell proliferation | CURIS, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050070578-A1 | Small organic molecule regulators of cell proliferation | CURIS, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050070578-A1 | Small organic molecule regulators of cell proliferation | CURIS, INC. | 2005-03-31 | — | — | US | disclosed |
| US-6828427-B1 | Oligomeric aminodiol-containing compounds, libraries thereof, and process of preparing the same | ISIS PHARMACEUTICALS, INC. | 2004-12-07 | — | — | US | disclosed |
| WO-2004085403-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-10-07 | — | — | WO | disclosed |
| EP-1436287-A2 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | Curis, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6750344-B1 | MONOCYCLIC AMINE SCAFFOLD BEARING AT LEAST TWO SITES OF DIVERSITY, CYCLIZED TO FORM BICYCLIC AMINE SCAFFOLDS; 7-AMINO-PYRROLO(1,2-A)PYRAZIN-4-ONE COMPOUNDS | ISIS PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20040110754-A1 | 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide for example; for pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004047738-A2 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040087798-A1 | Novel amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | US | disclosed |
| US-20040082079-A1 | Low affinity screening method | GRAFFINITY PHARMACEUTICALS AG. (DE) | 2004-04-29 | — | — | US | disclosed |
| WO-2004021969-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2004-03-18 | — | — | WO | disclosed |
| WO-2003027234-A9 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | CURIS INC (US) | 2004-02-19 | — | — | WO | disclosed |
| US-6610714-B2 | HIV viricides | MEDIVIR AB (SE) | 2003-08-26 | — | — | US | disclosed |
| US-20030139457-A1 | Small organic molecule regulators of cell proliferation | CURIS, INC. | 2003-07-24 | — | — | US | disclosed |
| US-20030092743-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2003-05-15 | — | — | US | disclosed |
| WO-2003027234-A2 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | CURIS, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
| US-6504057-B2 | Anti-arrhythmia, -ischemic, -proliferative and -diabetic agents; cardiotonic, necrosis; angina pectoris; peripheral and central nervous systems; protecting/preserving organs; inhibition of Na+/H+ exchange; diagnosis hypertonia | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-01-07 | — | — | US | disclosed |
| EP-1264820-A1 | NOVEL AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
| US-6469010-B1 | COMPOSITION ALSO FOR ALLEVIATION OR TREATMENT OF SYMPTOMS DERIVED FROM SEIZURES, EPILEPSY AND MIGRAINE HEADACHES, AND SUPPRESSION OF CALCIUM ION OVERLOAD | SUNTORY LIMITED (JP) | 2002-10-22 | — | — | US | disclosed |
| US-6465485-B1 | SUCH AS 7-CYANO-2-(2-(1-(4-(2-INDOLYL)CARBOXAMIDO)CYCLO-HEXYL)ETHYL)-1,2,3,4 -TETRAHYDROISOQUINOLINE; ANTIPSYCHOTIC AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-10-15 | — | — | US | disclosed |
| US-20020127577-A1 | Bioactive sensors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-09-12 | — | — | US | disclosed |
| US-20020123529-A1 | Anti-arrhythmia, -ischemic, -proliferative and -diabetic agents; cardiotonic, necrosis; angina pectoris; peripheral and central nervous systems; protecting/preserving organs; inhibition of Na+/H+ exchange; diagnosis hypertonia | HOECHST AKTIENGESELLSCHAFT | 2002-09-05 | — | — | US | disclosed |
| US-6316626-B1 | Amine compounds and combinatorial libraries comprising same | ISIS PHARMACEUTICALS, INC. | 2001-11-13 | — | — | US | disclosed |
| US-20010020042-A1 | Cardiovascular disorders | HOECHST AKTIENGESELLSCHAFT | 2001-09-06 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| US-6048876-A | ANTICONVULSANTS; ANTIEPILEPIC AGENT | SUNTORY LIMITED (JP) | 2000-04-11 | — | — | US | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0865439-A4 | COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS | ISIS PHARMACEUTICALS INC (US) | 1998-11-11 | — | — | EP | disclosed |
| EP-0865439-A1 | COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-23 | — | — | EP | disclosed |
| EP-0755923-A1 | AMELIORANT OR REMEDY FOR SYMPTOMS CAUSED BY ISCHEMIC DISEASES AND COMPOUNDS USEFUL THEREFOR | SUNTORY LIMITED (JP) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996040672-A1 | COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040672-A1 | COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (38 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172442-A1 | AMINO ACID DERIVATIVE | OPRL1, OPRK1, SLC1A1 | TDO2 1960/4885MIF 1123/4885NFE2L2 1218/4885 |
| US-20080193423-A1 | Small organic molecule regulators of cell proliferation | GLI1, SHH, SMO | TDO2 1709/4885MIF 1057/4885NFE2L2 2311/4885 |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | TDO2 2798/4885MIF 4348/4885NFE2L2 686/4885 |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | TDO2 1024/4885MIF 3696/4885NFE2L2 4821/4885 |
| US-20020123529-A1 | Anti-arrhythmia, -ischemic, -proliferative and -diabetic agents; cardiotonic, necrosis; angina pectoris; peripheral and central nervous systems; protecting/preserving organs; inhibition of Na+/H+ exchange; diagnosis hypertonia | TNNI3, SLC5A1, TNNC1 | TDO2 3830/4885MIF 1714/4885NFE2L2 1572/4885 |
| US-20120202787-A1 | Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators | BACE1, BACE2, GSAP | TDO2 4134/4885MIF 2800/4885NFE2L2 3095/4885 |
| US-20080058521-A1 | Processes for the preparation of compounds | MKI67, MCL1, DCX | TDO2 3236/4885MIF 1847/4885NFE2L2 485/4885 |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | PTPRCAP, PTPN2, PTPRC | TDO2 754/4885MIF 1653/4885NFE2L2 2691/4885 |
| US-20090092975-A1 | SELECTABLE MARKER | AMD1, PADI1, PSAT1 | TDO2 899/4885MIF 3264/4885NFE2L2 4529/4885 |
| US-20120245184-A1 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | GLI1, SHH, SMO | TDO2 1709/4885MIF 1057/4885NFE2L2 2311/4885 |
| US-20060287385-A1 | Small organic molecule regulators of cell proliferation | GLI1, SHH, SMO | TDO2 2367/4885MIF 765/4885NFE2L2 1928/4885 |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | TDO2 1024/4885MIF 3696/4885NFE2L2 4821/4885 |
| US-20080194637-A1 | Small organic molecule regulators of cell proliferation | GLI1, SHH, SMO | TDO2 1709/4885MIF 1057/4885NFE2L2 2311/4885 |
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | TDO2 47/4885MIF 1734/4885NFE2L2 1266/4885 |
| US-20080207740-A1 | tert-Butyl {4-[(4'-cyano-4-methoxy-biphenyl-3-ylmethyl)-amino]-cyclohexyl}-methyl-carbamate; hedgehog pathway agonists; to modulate proliferation or differentiation in a cell or tissue in vivo or vitro; alopecia; angiogenesis; wound healing; alzheimer's disease; to inhibit aging effects on skin | SHH, GLI1, SMO | TDO2 2001/4885MIF 1946/4885NFE2L2 1199/4885 |
| US-20040110754-A1 | 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide for example; for pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders | KCNQ2, KCNQ5, KCNJ2 | TDO2 4067/4885MIF 4170/4885NFE2L2 1360/4885 |
| US-20060178515-A1 | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | TDO2 1978/4885MIF 1258/4885NFE2L2 1272/4885 |
| US-20230044323-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | NFATC1, MYD88, ICOS | TDO2 3627/4885MIF 311/4885NFE2L2 1313/4885 |
| US-20100137353-A1 | TRICYCLIC COMPOUNDS AS ANTIBACTERIALS | NRDC, NACA, NOP2 | TDO2 785/4885MIF 2141/4885NFE2L2 2043/4885 |
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | TDO2 3091/4885MIF 413/4885NFE2L2 1804/4885 |
| US-20080153873-A1 | DIHYDROBENZOFURANYL DERIVATIVES AND METHODS OF THEIR USE | DBH, SLC6A3, SLC6A4 | TDO2 614/4885MIF 1110/4885NFE2L2 508/4885 |
| US-20100221398-A1 | PRESERVATIVE | C9, AOX1, MANBA | TDO2 1427/4885MIF 217/4885NFE2L2 81/4885 |
| US-20080182859-A1 | tert-Butyl {4-[(4'-cyano-4-methoxy-biphenyl-3-ylmethyl)-amino]-cyclohexyl}-methyl-carbamate; hedgehog pathway agonists; to modulate proliferation or differentiation in a cell or tissue in vivo or vitro; alopecia; angiogenesis; wound healing; alzheimer's disease; to inhibit aging effects on skin | SHH, GLI1, SMO | TDO2 1884/4885MIF 2630/4885NFE2L2 1257/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | TDO2 83/4885MIF 1696/4885NFE2L2 3435/4885 |
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | TDO2 3091/4885MIF 413/4885NFE2L2 1804/4885 |
| US-20030139457-A1 | Small organic molecule regulators of cell proliferation | GLI1, SHH, SMO | TDO2 2367/4885MIF 765/4885NFE2L2 1928/4885 |
| US-20110071155-A1 | Tricyclic Nitrogen Containing Compounds And Their Use As Antibacterials | CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYCS | TDO2 547/4885MIF 3859/4885NFE2L2 1557/4885 |
| US-20150239931-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTP4A2, PTPRF, PTPA | TDO2 911/4885MIF 3097/4885NFE2L2 2840/4885 |
| US-20030092743-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | SUB1, HCFC1, CCR1 | TDO2 2508/4885MIF 4261/4885NFE2L2 4375/4885 |
| US-20050070578-A1 | Small organic molecule regulators of cell proliferation | GLI1, SHH, SMO | TDO2 2367/4885MIF 765/4885NFE2L2 1928/4885 |
| US-20010020042-A1 | Cardiovascular disorders | SLC5A1, SLC9A1, SLC28A1 | TDO2 2861/4885MIF 1447/4885NFE2L2 2265/4885 |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR2H, POLR2E, POLR1E | TDO2 2183/4885MIF 4205/4885NFE2L2 3280/4885 |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | TDO2 2956/4885MIF 4730/4885NFE2L2 839/4885 |
| US-20040087798-A1 | Novel amide compounds | H1-2, H1-0, H1-3 | TDO2 278/4885MIF 3408/4885NFE2L2 591/4885 |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | TDO2 1024/4885MIF 3696/4885NFE2L2 4821/4885 |
| US-20080070951-A1 | Non-Nucleotide Reverse Transcriptase Inhibitors | RCOR1, RRM2, POLR1A | TDO2 2012/4885MIF 3535/4885NFE2L2 4350/4885 |
| US-20090005368-A1 | such as 6-({trans-4-[(1R)-1-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-cyclohexylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one for treating infections from Streptococcus pneumoniae, Haemophilus influenzae, Moraxella, Staphylococcus, Enterococcus | RBPJ, RXRA, MRPL21 | TDO2 189/4885MIF 1122/4885NFE2L2 874/4885 |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | TDO2 3091/4885MIF 413/4885NFE2L2 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.